Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Decentralized clinical trials continue to gain ground

By Brian Buntz | May 25, 2021

clinical trials pharmaceuticals pharmaceutical

[Photo by Laura James from Pexels]

The COVID-19 pandemic has led to fundamental changes in how pharmaceutical companies and physicians interact with patients.

And yet — for all of the talk about digital transformation, artificial intelligence (AI) and decentralized clinical trials in medicine in recent years — the adoption of those concepts has lagged. “The reality is that we’ve gone after shiny objects in many places,” said Dr. Nirav Shah, chief medical officer of Sharecare (Atlanta, Ga.).

The situation is, however, swiftly changing thanks to the pandemic. Some 44% of pharma, biotech and clinical research professionals have already adopted remote patient monitoring (RPM) or plan to do so in the next 12 months, according to a recent survey from VivaLNK (Campbell, Calif.). Almost two-thirds (65%) of survey respondents reported the pandemic was the primary driver of RPM adoption.

Physicians have witnessed a similar trend with telemedicine, which encompasses telephone and video-based remote visits. “We’ve talked about telemedicine for many, many years,” Shah said, who also a senior scholar at Stanford University. “COVID, overnight, changed the adoption of telemedicine from 0% for primary care visits at Stanford to 75%.”

While telemedicine adoption has fallen from its peak in the early days of the pandemic, there is now an inflection point that has made medical professionals and patients more aware of the possibility of remote care.

Clinical trial shifts have followed a similar trajectory. During the pandemic, many physicians saw the power of remotely gathered health metrics. A patient could answer the Patient Health Questionnaire (PHQ)-9 for depression in a clinic or via a smartphone. Using a smartphone to ask patients about depression symptoms enables potentially more frequent monitoring.

Gathering data via smartphones also enables physicians to better understand how patients’ lived experience affects their health while avoiding phenomena such as white-coat hypertension, where patients’ blood pressure spikes when they physically visit a doctor’s office. “We can get better data using patient-reported outcome measures,” Shah said.

Smartphones paired with artificial intelligence can also provide patients with insightful health information in clinical research. Sharecare, for instance, has explored using machine learning to predict allergy symptom burden and symptom severity for allergic rhinitis.

The smartphone also enables physicians to improve care for underserved and vulnerable populations, Shah said. “There’s a digital divide when it comes to rural broadband use. There’s no digital divide, according to a Pew 2019 survey, when it comes to families owning a smartphone with a cellular plan,” he explained. Using the smartphone to gather patient health information reduces the need for patients in rural areas to travel long distances to seek medical care.

It also can optimize clinical trial retention and data gathering. “In our asthma and allergy study with 2,000 people, we had one person drop out after a year,” Shah said. “We had 10% of patients enrolled in the clinical trial fill out allergy symptoms every single day for a year.”

Remote and hybrid trial designs can also facilitate patient selection. “Traditionally, patient selection was extremely burdensome,” Shah said. “If you didn’t live within x miles of an academic medical center, you couldn’t get enrolled in clinical trials in the past.”

Doing clinical trials for rare disease poses further challenges, Shah said. Sharecare did a study on myasthenia gravis, a rare condition that results from suboptimal communication between muscles and nerves. “It’s very hard to recruit for myasthenia gravis because it’s a rare disease, and you need to recruit so many medical centers,” Shah said.

Using a virtual platform, however, Sharecare was able to recruit patients for a myasthenia gravis trial within one day and receive 325 patient responses. Remote clinical trials also improve “follow up with longitudinal, even post-market surveillance, in ways that you couldn’t do with a traditional clinical trial,” Shah said.

Pharmaceutical companies seeking to launch clinical trials in a post-pandemic world should let go of the idea of traditional clinical trials where patients come into an academic medical center, Shah said. Instead, they should start with the concept of an entirely virtual trial and “then back into the few things that you need in the traditional model,” he said.

“If you’re a drug company, imagine monitoring using the smartphone in ways that you could never do if patients wrote diary entries,” Shah said. “You can push out notifications after a COVID vaccine and ask, ‘Which of the following seven symptoms have you had a day later?” Shah asked. “You can capture things with smartphones and edge devices in ways that you couldn’t capture at scale efficiently with any budget in the old world.”


Filed Under: clinical trials, Drug Discovery, Infectious Disease
Tagged With: AI, artificial intelligence, covid-19, COVID-19 vaccine, decentralized clinical trials., Sharecare, smartphone, telemedicine
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE